Governance OncoSil Medical Limited

OSL

AU000000OSL3

Pharmaceuticals

Delayed Australian S.E. Other stock markets 06:00:50 2025-12-08 pm EST			5-day change	1st Jan Change
1.045 ^AUD	-0.95%		-6.07%	-56.46%

Nov. 02	OncoSil Medical Limited Announces Retirement of Doug Cubbin as Independent Non-Executive Director	CI
Oct. 15	OncoSil Medical Reports First Pancreatic Cancer Device Treatment in Germany	MT

Executive Committee: OncoSil Medical Limited

Manager

Positions heldSince

Nigel Lange

Chief Executive Officer

2021-01-20

David Turner

Chief Tech/Sci/R&D Officer

2020-12-31

Henk Tissing

Chief Tech/Sci/R&D Officer

Jon Bell

Chief Tech/Sci/R&D Officer

Tim Luscombe

Corporate Secretary

2025-08-31

Composition of the Board of Directors: OncoSil Medical Limited

Director

CommitteesSince

Thomas Duthy

Chairman

2025-09-30

Peter James MacDonald Hall

Compensation Committee	2011-01-06
Nominating Committee	2011-01-06

Nigel Lange

Director/Board Member

2021-01-20

Latest Appointments: OncoSil Medical Limited

Nov. 02	OncoSil Medical Limited Announces Retirement of Doug Cubbin as Independent Non-Executive Director	CI
Sep. 08	Oncosil Medical appoints Thomas Duthy as Non-Executive Chairman	RE
Sep. 08	OncoSil Medical Promotes Thomas Duthy to Non-Executive Chairman; Shares Jump 13%	MT
Sep. 01	OncoSil Medical Limited Announces Executive Changes, Effective September 1, 2025	CI
Jul. 23	Oncosil Medical Limited Announces Change of Company Secretary, Effective 23 July 2025	CI
Jul. 10	Oncosil Medical Limited Announces Board Changes, Effective from 11 July 2025	CI
Mar. 31	OncoSil Medical Limited Announces Changes to Company Secretary, Effective April 1, 2025	CI

More news

Former Officers and Directors: OncoSil Medical Limited

Insider

Positions held

SinceUntil

Douglas Cubbin

Director/Board Member	2025-09-30	2025-11-18
Chairman	2023-08-30	2025-09-30

Nathan Jong

Corporate Secretary

2025-03-31

2025-07-22

Gabriel Liberatore

Director/Board Member

2023-07-13

2025-07-10

Christian Cin

Director of Finance/CFO	2023-05-31	2025-03-30
Corporate Secretary	2023-05-31	2025-03-30

Otto Buttula

Director/Board Member	2021-07-19	2021-10-18
Chairman	2021-10-18	2023-08-30

Karl Pechmann

Director of Finance/CFO	2020-03-30	2023-05-23
Corporate Secretary	2020-03-30	2023-05-23

Martin Cross

Director/Board Member	2017-02-27	2022-10-23
Independent Dir/Board Member	2017-02-27	2022-10-23

Ricky Sharma

Director/Board Member

2021-10-31

Michael Bassett

Director/Board Member

2018-12-09

2021-10-18

Chris Roberts

Director/Board Member	2016-01-20	2017-05-07
Chairman	2017-05-07	2021-10-18
Independent Dir/Board Member	2016-01-20	2017-05-07

Roger Aston

Director/Board Member	2017-05-07	2021-10-18
Chairman	2014-09-08	2017-05-07
Independent Dir/Board Member	2013-03-27	2014-09-08

Michael Warrener

Sales & Marketing

2016-06-30

2021-06-30

Ralph Peters

Chief Tech/Sci/R&D Officer

2021-02-09

Daniel Kenny

Director/Board Member	2014-11-27	2020-12-01
Chief Executive Officer	2014-11-27	2020-12-01

Tom Milicevic

Director of Finance/CFO	2015-10-21	2019-09-26
Corporate Secretary	2015-10-21	2019-09-26

Ashish Soman

Chief Tech/Sci/R&D Officer

2015-06-03

2019-09-19

Peter Casey

Corporate Secretary

2014-02-26

2015-10-21

Nick Falzon

Comptroller/Controller/Auditor	2013-08-25	2015-10-21
Director of Finance/CFO	2013-08-22	2015-10-21
Corporate Secretary	2013-08-25	2015-10-21
Director of Finance/CFO	2019-09-26	2020-03-30
Corporate Secretary	2019-09-26	2020-03-30

Lawrence Gozlan

Director/Board Member	2014-02-26	2015-05-03
Independent Dir/Board Member	2014-02-26	2015-05-03

David James

Chief Operating Officer

2014-12-31

Neil Frazer

Director/Board Member	2013-07-01	2014-11-27
Chief Executive Officer	2013-07-01	2014-09-08
Chief Tech/Sci/R&D Officer	2014-09-08	2014-11-27

Natalie Ruffles

Chief Tech/Sci/R&D Officer

2014-02-12

Brian Leedman

Founder	2013-03-31	2013-12-31
Director/Board Member	2022-09-14	2023-11-28

Jillian McGregor

General Counsel	2013-07-01	2013-08-25
Corporate Secretary	2013-07-01	2013-08-25

Simon O'Loughlin

Director/Board Member	2012-03-14	2013-05-31
Independent Dir/Board Member	2012-03-14	2013-05-31

Martin Rogers

Director/Board Member	2014-09-08	-
Chairman	2013-07-01	2014-09-08
Independent Dir/Board Member	2013-04-02	2014-09-08

Neville Bassett

Director/Board Member

2012-03-13

Michael Anthony Robson

Chairman

2010-11-21

2011-12-11

Bret Wayne Mattes

Chairman	2011-12-11	-
Independent Dir/Board Member	2011-12-11	-

Morgan Barron

Corporate Secretary

2010-12-20

Robert Hodby

Corporate Secretary

2010-12-02

Harry Karelis

Chairman

2010-03-04

2010-10-06

Jonathan Treherne

Chairman

2010-03-04

John Hannaford

Director/Board Member

2009-07-30

Iain Chessell

President

2008-04-07

2009-06-14

Narelle Warren

Corporate Secretary

2007-09-30

2008-09-25

Mark Bianchini

Corporate Secretary

2007-02-28

Narelle Lloyd

Corporate Secretary

2007-02-28

David McAuliffe

Director/Board Member	2011-12-31	-
Founder	2005-04-13	-

Aoifa Brogan

General Counsel

Kevin Lee

Founder

Peter Knox

Chief Tech/Sci/R&D Officer

Nicole Wilson

General Counsel

Tony King

Director/Board Member

2010-12-01

Age distribution of managers

Parity Men Women

Male	7
Female	0

Of which Executive Committee

Male	5
Female	0

Of which Directors

Male	3
Female	0

OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

Employees

Sector

Pharmaceuticals

Calendar

Mar. 03 - Q2 2026 Earnings Release (Projected)

More about the company